Herr Daniel L, Sum-Ping S T John, England Michael
Washington Hospital Center, Washington, DC 2010, USA.
J Cardiothorac Vasc Anesth. 2003 Oct;17(5):576-84. doi: 10.1016/s1053-0770(03)00200-3.
To compare dexmedetomidine-based to propofol-based sedation after coronary artery bypass graft (CABG) surgery in the intensive care unit (ICU).
Randomized, open label.
Twenty-five centers in the United States and Canada.
Two hundred ninety-five adults undergoing CABG surgery.
At sternal closure, patients in group A received 1.0 microg/kg of dexmedetomidine over 20 minutes and then 0.2 to 0.7 microg/kg/h to maintain a Ramsay sedation score > or =3 during assisted ventilation and > or =2 after extubation. Patients could be given propofol for additional sedation if necessary; group B patients received propofol-based care according to each investigator's standard practice.
Mean sedation levels were within target ranges in both groups. Mean times to weaning and extubation were similar, although fewer dexmedetomidine patients remained on the ventilator beyond 8 hours. Morphine use was significantly reduced in the dexmedetomidine group. Only 28% of the dexmedetomidine patients required morphine for pain relief while ventilated versus 69% of propofol-based patients (p < 0.001). Propofol patients required 4 times the mean dose of morphine while in the ICU. Mean blood pressure increased initially in both groups, then decreased to 3 mmHg below baseline in dexmedetomidine patients; mean arterial pressure remained at 9 mmHg above baseline in propofol patients. No ventricular tachycardia occurred in the dexmedetomidine-sedated patients compared with 5% of the propofol patients (p = 0.007). Respiratory rates and blood gases were similar. Fewer dexmedetomidine patients received beta-blockers (p = 0.014), antiemetics (p = 0.015), nonsteroidal anti-inflammatory drugs (p < 0.001), epinephrine (p = 0.030), or high-dose diuretics (p < 0.001).
Dexmedetomidine provided safe and effective sedation for post-CABG surgical patients and significantly reduced the use of analgesics, beta-blockers, antiemetics, epinephrine, and diuretics.
比较在重症监护病房(ICU)中,冠状动脉旁路移植术(CABG)后使用右美托咪定镇静与使用丙泊酚镇静的效果。
随机、开放标签。
美国和加拿大的25个中心。
295例接受CABG手术的成年人。
在胸骨闭合时,A组患者在20分钟内接受1.0微克/千克的右美托咪定,然后以0.2至0.7微克/千克/小时的速度给药,以在辅助通气期间维持 Ramsay 镇静评分≥3,拔管后维持评分≥2。如有必要,患者可给予丙泊酚进行额外镇静;B组患者根据每位研究者的标准做法接受基于丙泊酚的护理。
两组的平均镇静水平均在目标范围内。脱机和拔管的平均时间相似,尽管使用右美托咪定的患者在8小时后仍使用呼吸机的人数较少。右美托咪定组的吗啡使用量显著减少。在使用呼吸机时,只有28%的右美托咪定患者需要吗啡止痛,而基于丙泊酚的患者中这一比例为69%(p<0.001)。在ICU期间,丙泊酚组患者所需吗啡的平均剂量是右美托咪定组的4倍。两组患者的平均血压最初均升高,然后右美托咪定组患者的平均血压降至基线以下3 mmHg;丙泊酚组患者的平均动脉压保持在基线以上9 mmHg。与5%使用丙泊酚的患者相比,使用右美托咪定镇静的患者未发生室性心动过速(p = 0.007)。呼吸频率和血气指标相似。使用右美托咪定的患者接受β受体阻滞剂(p = 0.014)、止吐药(p = 0.015)、非甾体抗炎药(p<0.001)、肾上腺素(p = 0.030)或大剂量利尿剂(p<0.001)的人数较少。
右美托咪定为CABG术后患者提供了安全有效的镇静,并显著减少了镇痛药、β受体阻滞剂、止吐药、肾上腺素和利尿剂的使用。